Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study.
作者： A. Ameri , M. Poisson , L. Chauveinc , Q.M. Chen , JY Delattre
关键词:
摘要: Thirty one patients previously treated with surgery, radiation therapy and chemotherapy a nitrosoureafor malignant supratentorial gliomas received combination of carboplatin (CBDCA) etoposide(VP16) at tumor progression. Carboplatin etoposide(CE) were given, each dose 100 mg/m2/day from day 1 to 3. The response was evaluated course minimum three courses required definite stable patient.Tolerance in 31 patients. None had renalor auditory toxicity. Side effects consisted grade III hematologic toxicity 6 (19%), hepatic patient. No gradeIV WHO observed.All could be for therapeutic response.A partial noted 4 during 13, 34 +, 35 + 51 weeks. Ten stabledisease after 3 (19 37 weeks). rate (PR)and stabilisation (S) 45% (14/31). median time progression (MTTP) respondingand 28 survival time(ST) the entire group 45 weeks over PR S
springer.com
sci-hub.se 参考文章(11)
B Jeremic, D Grujicic, S Jevremovic, B Stanisavljevic, L Milojevic, L Djuric, L Mijatovic, Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. Journal of Clinical Oncology. ,vol. 10, pp. 1074- 1077 ,(1992) , 10.1200/JCO.1992.10.7.1074
W K Yung, L Mechtler, M J Gleason, Intravenous carboplatin for recurrent malignant glioma: a phase II study. Journal of Clinical Oncology. ,vol. 9, pp. 860- 864 ,(1991) , 10.1200/JCO.1991.9.5.860
A. Boiardi, A. Silvani, I. Milanesi, M. Botturi, G. Broggi, Primary glial tumor patients treated by combining cis-platin and etoposide Journal of Neuro-oncology. ,vol. 11, pp. 165- 170 ,(1991) , 10.1007/BF02390176
M. Poisson, Y. P�r�on, J. Chiras, J. Y. Delattre, Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). Journal of Neuro-oncology. ,vol. 10, pp. 139- 144 ,(1991) , 10.1007/BF00146875
Joseph Aisner, Edward J. Lee, Etoposide. Current and future status Cancer. ,vol. 67, pp. 215- 219 ,(1991) , 10.1002/1097-0142(19910101)67:1+<215::AID-CNCR2820671302>3.0.CO;2-D
Michael D. Walker, Sylvan B. Green, David P. Byar, Eben Alexander, Ulrich Batzdorf, William H. Brooks, William E. Hunt, Collin S. MacCarty, M. Stephen Mahaley, John Mealey, Guy Owens, Joseph Ransohoff, James T. Robertson, William R. Shapiro, Kenneth R. Smith, Charles B. Wilson, Thomas A. Strike, Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery New England Journal of Medicine. ,vol. 303, pp. 1323- 1329 ,(1980) , 10.1056/NEJM198012043032303
Luis A. Rodriguez, Michael Prados, Pamela Silver, Victor A. Levin, Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors Cancer. ,vol. 64, pp. 2420- 2423 ,(1989) , 10.1002/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B
Lynn G. Feun, Sidney Wallace, David J. Stewart, Vincent P. Chuang, Wai-Kwan A. Yung, Milam E. Leavens, M. Andrew Burgess, Niramol Savaraj, Robert S. Benjamin, Sue Ellen Young, Rosa Ann Tang, Stanley Handel, Giora Mavligit, William S. Fields, Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer. ,vol. 54, pp. 794- 799 ,(1984) , 10.1002/1097-0142(19840901)54:5<794::AID-CNCR2820540503>3.0.CO;2-F
H. B. Newton, L. Junck, J. Bromberg, M. A. Page, H. S. Greenberg, Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure Neurology. ,vol. 40, pp. 1743- 1746 ,(1990) , 10.1212/WNL.40.11.1743
E H Kovnar, S J Kellie, M E Horowitz, R A Sanford, J W Langston, R K Mulhern, J J Jenkins, E C Douglass, E E Etcubanas, D L Fairclough, Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. Journal of Clinical Oncology. ,vol. 8, pp. 330- 336 ,(1990) , 10.1200/JCO.1990.8.2.330